PMID: 2111239Mar 1, 1990Paper

Insulin and sulphonylurea in the therapy of type 2 diabetes

Diabetes Research and Clinical Practice
E A SotaniemiK Rytömaa

Abstract

The role of insulin in the therapy of NIDDM is still under discussion. To clarify the problem we performed a randomized double-blind placebo controlled crossover study of insulin treatment for 4 weeks in diabetic patients (n = 18, age 52-74 years) who were unsatisfactorily controlled by oral antidiabetic agents. The patients continued to use these agents during the study. Special attention was given to informing the patients about the trial and, in particular, about self-monitoring the blood glucose by the use of a reflectance meter. Insulin treatment produced the following significant changes: decreases in blood glucose (at 7.00, 10.00, 16.00), mean daily blood glucose, HbA1, urinary glucose and low density lipoprotein (LDL) cholesterol and increased postglucose immunoreactive insulin (IRI) levels. Significant changes were also observed during the placebo periods: decreases in HbA1 urinary glucose and LDL cholesterol (but not in blood glucose). Therapy with insulin increased the body weight, whereas the placebo insulin had the opposite effect. The finding emphasizes the importance of using not only a run-in period but also a placebo design when the metabolic effects of antidiabetes therapy are to be evaluated. The study indica...Continue Reading

References

Apr 7, 1977·The New England Journal of Medicine·S W Shen, R Bressler
Mar 1, 1979·Diabetologia·R W Stout
Jan 1, 1976·The American Journal of Medicine·G M ReavenJ M Olefsky
Sep 1, 1987·Diabetic Medicine : a Journal of the British Diabetic Association·R R HolmanR C Turner
Aug 23, 1985·The American Journal of Medicine·G Boden
Oct 1, 1987·Postgraduate Medical Journal·R B Tattersall, A R Scott
May 15, 1986·The New England Journal of Medicine·D B Martin
Aug 15, 1986·JAMA : the Journal of the American Medical Association·R M WilsonR B Tattersall
Jan 1, 1987·Diabetes Care·P S SharpE M Kohner
Jan 17, 1983·The American Journal of Medicine·R A DeFronzoV Koivisto
May 1, 1984·Diabetes Care·P I SalmelaO Mäentausta
Jul 1, 1982·Diabetes Care·J A ScarlettO G Kolterman
Jun 1, 1983·Clinical Pharmacology and Therapeutics·E A SotaniemiS Sutinen
Jun 1, 1954·The American Journal of Medicine·L LASAGNAH K BEECHER
Dec 24, 1955·Journal of the American Medical Association·H K BEECHER
Oct 17, 1959·British Medical Journal·A BLOOM
Oct 1, 1959·The American Journal of Psychiatry·A K SHAPIRO

❮ Previous
Next ❯

Citations

Jan 1, 1995·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·I KlebovichE A Sotaniemi
Oct 21, 2003·The Annals of Pharmacotherapy·Mary U Kabadi, Udaya M Kabadi
Oct 1, 2015·The Cochrane Database of Systematic Reviews·Antonio SaenzDavid Moher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.